Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Earnings for Immunovant, Inc. (IMVT)
Earnings in 2024 (TTM): $-258,769,000
According to Immunovant, Inc.'s latest financial reports the company's current earnings (TTM) are $-258,769,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Immunovant, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-258,769,000 | $-259,336,000 |
| 2023 | $-210,951,000 | $-210,960,000 |
| 2022 | $-156,814,000 | $-156,730,000 |
| 2021 | $-107,789,000 | $-107,431,000 |
| 2020 | $-66,291,000 | $-66,388,000 |
| 2019 | $-448 | $-448 |
| 2018 | $-136,740,000 | $-136,740,000 |